Ignite Creation Date:
2025-12-24 @ 12:22 PM
Ignite Modification Date:
2026-01-25 @ 9:17 PM
Study NCT ID:
NCT03959761
Status:
COMPLETED
Last Update Posted:
2025-12-19
First Post:
2019-05-21
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Tolerance of Intraperitoneal (IP) Nivolumab After Extensive Debulking Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Ovarian Carcinoma
Sponsor:
Hospices Civils de Lyon
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2019-10-17
Start Date Type:
ACTUAL
Primary Completion Date:
2022-10-03
Primary Completion Date Type:
ACTUAL
Completion Date:
2022-10-03
Completion Date Type:
ACTUAL
First Submit Date:
2019-05-21
First Submit QC Date:
None
Study First Post Date:
2019-05-22
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-12-13
Last Update Post Date:
2025-12-19
Last Update Post Date Type:
ESTIMATED